Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Accumulated Expenses (2017 - 2025)

Puma Biotechnology's Accumulated Expenses history spans 9 years, with the latest figure at $567000.0 for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 92.89% year-over-year to $567000.0; the TTM value through Dec 2025 reached $567000.0, down 92.89%, while the annual FY2025 figure was $567000.0, 92.89% down from the prior year.
  • Accumulated Expenses reached $567000.0 in Q4 2025 per PBYI's latest filing, down from $8.9 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $61.8 million in Q1 2022 to a low of $567000.0 in Q4 2025.
  • Average Accumulated Expenses over 5 years is $12.7 million, with a median of $5.1 million recorded in 2021.
  • Peak YoY movement for Accumulated Expenses: crashed 97.99% in 2021, then surged 3008.14% in 2022.
  • A 5-year view of Accumulated Expenses shows it stood at $5.1 million in 2021, then skyrocketed by 943.36% to $53.0 million in 2022, then tumbled by 88.88% to $5.9 million in 2023, then soared by 35.19% to $8.0 million in 2024, then plummeted by 92.89% to $567000.0 in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Accumulated Expenses are $567000.0 (Q4 2025), $8.9 million (Q3 2025), and $31.8 million (Q2 2025).